166 related articles for article (PubMed ID: 15378729)
21. Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms.
Wu W; Luo Y; Sun C; Liu Y; Kuo P; Varga J; Xiang R; Reisfeld R; Janda KD; Edgington TS; Liu C
Cancer Res; 2006 Jan; 66(2):970-80. PubMed ID: 16424032
[TBL] [Abstract][Full Text] [Related]
22. Multiple catalytic aldolase antibodies suitable for chemical programming.
Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Abraham S; Guo F; Li LS; Rader C; Liu C; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5584-9. PubMed ID: 17372220
[TBL] [Abstract][Full Text] [Related]
24. A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.
Grinda M; Clarhaut J; Tranoy-Opalinski I; Renoux B; Monvoisin A; Cronier L; Papot S
ChemMedChem; 2011 Dec; 6(12):2137-41. PubMed ID: 21815268
[No Abstract] [Full Text] [Related]
25. Reaction properties of catalytic antibodies encapsulated in organo substituted SiO2 sol-gel materials.
Kato K; Saito T; Seelan S; Tomita M; Yokogawa Y
J Biosci Bioeng; 2005 Oct; 100(4):478-80. PubMed ID: 16310742
[TBL] [Abstract][Full Text] [Related]
26. Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy.
Stevenson RJ; Denny WA; Tercel M; Pruijn FB; Ashoorzadeh A
J Med Chem; 2012 Mar; 55(6):2780-802. PubMed ID: 22339090
[TBL] [Abstract][Full Text] [Related]
27. Sulfonyl-containing nucleoside phosphotriesters and phosphoramidates as novel anticancer prodrugs of 5-fluoro-2'-deoxyuridine 5'-monophosphate (FdUMP).
Sun YW; Chen KM; Kwon CH
Mol Pharm; 2006; 3(2):161-73. PubMed ID: 16579645
[TBL] [Abstract][Full Text] [Related]
28. Antibody-catalyzed benzoin oxidation as a mechanistic probe for nucleophilic catalysis by an active site lysine.
Sklute G; Oizerowich R; Shulman H; Keinan E
Chemistry; 2004 May; 10(9):2159-65. PubMed ID: 15112204
[TBL] [Abstract][Full Text] [Related]
29. NFkappaB activation and drug sensitivity in human neoplastic cells treated with anthracyclines.
Gruber BM; Anuszewska EL; Bubko I; Kasprzycka-Guttman T; Misiewicz I; Skupińska K; Fokt I; Piebe W
Acta Pol Pharm; 2008; 65(2):267-71. PubMed ID: 18666436
[TBL] [Abstract][Full Text] [Related]
30. Fabricating an intelligent cell-like nano-prodrug via hierarchical self-assembly based on the DNA skeleton for suppressing lung metastasis of breast cancer.
Li Y; Yan T; Chang W; Cao C; Deng D
Biomater Sci; 2019 Aug; 7(9):3652-3661. PubMed ID: 31169833
[TBL] [Abstract][Full Text] [Related]
31. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
[TBL] [Abstract][Full Text] [Related]
32. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
33. Modular Nanoparticulate Prodrug Design Enables Efficient Treatment of Solid Tumors Using Bioorthogonal Activation.
Miller MA; Mikula H; Luthria G; Li R; Kronister S; Prytyskach M; Kohler RH; Mitchison T; Weissleder R
ACS Nano; 2018 Dec; 12(12):12814-12826. PubMed ID: 30550257
[TBL] [Abstract][Full Text] [Related]
34. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
35. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
36. [Anticancer activity of N-(phenylacetyl) doxorubicin combined with folate-targeted PGA].
Zhang Q; Xiang GY; Long N; Lin JL; Zeng FB
Yao Xue Xue Bao; 2005 Nov; 40(11):1046-50. PubMed ID: 16499093
[TBL] [Abstract][Full Text] [Related]
37. A new spacer group derived from arylmalonaldehydes for glucuronylated prodrugs.
Papot S; Combaud D; Gesson JP
Bioorg Med Chem Lett; 1998 Sep; 8(18):2545-8. PubMed ID: 9873577
[TBL] [Abstract][Full Text] [Related]
38. The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy.
Stevenson RJ; Denny WA; Ashoorzadeh A; Pruijn FB; van Leeuwen WF; Tercel M
Bioorg Med Chem; 2011 Oct; 19(20):5989-98. PubMed ID: 21920763
[TBL] [Abstract][Full Text] [Related]
39. A macromolecular prodrug of doxorubicin conjugated to a biodegradable cyclotriphosphazene bearing a tetrapeptide.
Kim JK; Toti US; Song R; Sohn YS
Bioorg Med Chem Lett; 2005 Aug; 15(15):3576-9. PubMed ID: 15982876
[TBL] [Abstract][Full Text] [Related]
40. [The in vitro cytotoxicity and in vivo toxicity of doxorubicin antiresistant stealth liposomes].
Wang JC; Liu XY; Lü WL; Lee HS; Goh BC; Zhang Q
Yao Xue Xue Bao; 2005 May; 40(5):475-80. PubMed ID: 16220797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
